Receiveable Turnover: An accounting measure used to quantify a firm's effectiveness in extending credit as well as collecting debts. Calculated as: Total Revenues / Accounts Receivable
Adaptimmune Therapeutics PLC (ADAP) had Receiveable Turnover of 1.66 for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
$7.29M |
|
$-47.58M |
|
$0.88M |
|
$6.41M |
|
$53.02M |
|
$-45.73M |
|
$-1.28M |
|
$-47.01M |
|
$-47.01M |
|
$-47.58M |
|
$-47.58M |
|
$-47.58M |
|
$-47.58M |
|
$-45.73M |
|
$-43.27M |
|
257.03M |
|
257.03M |
|
$-0.18 |
|
$-0.18 |
|
| Balance Sheet Financials | |
$103.00M |
|
$29.72M |
|
$55.07M |
|
$158.07M |
|
$51.07M |
|
$25.41M |
|
$144.43M |
|
$195.50M |
|
$-37.43M |
|
$-41.23M |
|
$-37.43M |
|
257.85M |
|
| Cash Flow Statement Financials | |
$-66.59M |
|
$41.15M |
|
$-25.32M |
|
$93.21M |
|
$43.00M |
|
$-50.20M |
|
$0.67M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.02 |
|
-- |
|
-- |
|
-2.11 |
|
-0.68 |
|
87.93% |
|
-627.77% |
|
-627.77% |
|
-- |
|
-645.28% |
|
-653.18% |
|
$-67.80M |
|
-- |
|
-- |
|
-- |
|
0.05 |
|
0.07 |
|
|
Receiveable Turnover |
1.66 |
54.14 |
|
127.13% |
|
115.40% |
|
-30.10% |
|
395.94% |
|
$-0.15 |
|
$-0.26 |
|
$-0.26 |
|